Seoul, South Korea

Young Ho Moon

This inventor holds 7 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Gencurix Inc, Korea Institute of Science and Technology, Logone Bio Convergence Research Foundation. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Young Ho Moon. Retrieved from https://idiyas.com/inventor/young-ho-moon-fa6vz8eh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 71.4


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations by Inventor Young Ho Moon in Breast Cancer Prognosis and Nucleic Acid Quality Assessment

Introduction

Young Ho Moon, a prominent inventor based in Seoul, South Korea, has made significant contributions to the fields of biotechnology and healthcare through his innovative research and inventions. Holding a total of seven patents, Moon's work primarily focuses on methods for assessing nucleic acid quality in biological samples and predicting breast cancer prognosis.

Latest Patents

Among his latest patents, the invention titled "Method for Determining Nucleic Acid Quality of Biological Sample" stands out. This invention introduces a novel approach for evaluating the DNA quality of biological samples. By utilizing quantitative polymerase chain reaction (PCR) with specially designed primers, Moon's method allows researchers to objectively determine DNA quality, crucial for accurate gene analysis. This innovation provides more reliable insights into gene mutation expression ratios, which is invaluable in clinical research and companion diagnostics.

Another significant patent from Moon is the "Method for Predicting Prognosis of Breast Cancer Patient." This groundbreaking method outlines a procedure for predicting a breast cancer patient’s prognosis by measuring specific mRNA expression levels. By analyzing the expression levels of matrix metallopeptidase 11 (MMP11) and cluster of differentiation 2 (CD2), the method can accurately indicate the prognosis for patients, especially for those with the HER2-type breast cancer, which is notoriously challenging. This invention not only enhances prognostic accuracy but also aids in providing better treatment directions for breast cancer patients.

Career Highlights

Throughout his career, Young Ho Moon has been associated with reputable organizations, including Gencurix Inc and the Korea Institute of Science and Technology. His work within these institutions has facilitated the transition of innovative ideas into practical applications, leading to advancements in medical research.

Collaborations

Young Ho Moon has collaborated with esteemed colleagues such as Young Kee Shin and Sang Rae Cho. These collaborations have allowed for the cross-pollination of ideas and expertise, further enriching Moon's inventions and their impact on healthcare.

Conclusion

In summary, Young Ho Moon's contributions to the field of biotechnology through his patents reflect his commitment to improving healthcare solutions. His innovative methods for assessing nucleic acid quality and predicting breast cancer prognosis signify a notable advancement in medical technology, benefiting both researchers and patients alike.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…